Scholarlink

Objective <p>Owing to crucial role played by MicroRNA-126 (<i>mi</i>R-126) in vascular development and regulation of vascular endothelial growth factor (<i>VEGFA</i>), this study determined the role of <i>mi</i>R-126 and its target gene <i>VEGFA</i> in the pathogenesis of recurrent pregnancy loss (RPL) in women against healthy controls.</p> Methods <p>A total of 40 samples were collected from women who had experienced consecutive RPL at 20&#xa0;weeks of gestation when compared to healthy controls with full-term successful pregnancies. The relative expression of <i>mi</i>R-126 and <i>VEGFA</i> in plasma was quantified using quantitative real-time polymerase chain reaction (qRT-PCR).</p> Results <p><i>mi</i>R-126 expression was significantly up regulated in RPL patients compared to controls (p &lt; 0.0001), with a median fold change of 3.13 (IQR: 1.25–5.78). Conversely, <i>VEGFA m</i>RNA expression was significantly down regulated in RPL patients (p &lt; 0.0001), with a median fold change of 0.29 (IQR: 0.12–0.67). Moreover, no substantial differences were found in relative expression of <i>mi</i>R-126 and <i>VEGFA m</i>RNA among categories of various variables in RPL group respectively. Correlation analysis revealed a negative association between <i>mi</i>R-126 and <i>VEGFA</i> expression in RPL cases (r = -0.165). In healthy controls, the <i>mi</i>R-126 expression was positively correlated with expression levels of <i>VEGFA m</i>RNA with correlation coefficient (r) = 0.925; p &lt; 0.01. However, the correlation between <i>mi</i>R-126 and <i>VEGFA m</i>RNA was not statistically significant in the RPL group.</p> Conclusions <p>Our findings suggest that dysregulation of <i>mi</i>R-126 and <i>VEGFA</i> is associated with RPL. These markers may serve as potential diagnostic and prognostic tools for idiopathic RPL. Furthermore, restoring the normal expression of these molecules could represent a novel therapeutic approach for this condition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Significant Implications Of miR-126 Expression With Respect to Its Target Gene VEGFA in the Pathogenesis of Recurrent Pregnancy Losses (RPL)-a Study in High Incidence Zone

  • 期刊论文

  • 发表日期：

    2026年2月23日

查看全文
  • Ina Amin,
  • Arshad A. Pandith,
  • Usma Manzoor,
  • Shayaq Ul Abeer Rasool,
  • Syed Hussain Mir,
  • Dil Afroze,
  • Iqra Anwar,
  • Adil Lateef,
  • Abida Ahmad

摘要

Objective

Owing to crucial role played by MicroRNA-126 (miR-126) in vascular development and regulation of vascular endothelial growth factor (VEGFA), this study determined the role of miR-126 and its target gene VEGFA in the pathogenesis of recurrent pregnancy loss (RPL) in women against healthy controls.

Methods

A total of 40 samples were collected from women who had experienced consecutive RPL at 20 weeks of gestation when compared to healthy controls with full-term successful pregnancies. The relative expression of miR-126 and VEGFA in plasma was quantified using quantitative real-time polymerase chain reaction (qRT-PCR).

Results

miR-126 expression was significantly up regulated in RPL patients compared to controls (p < 0.0001), with a median fold change of 3.13 (IQR: 1.25–5.78). Conversely, VEGFA mRNA expression was significantly down regulated in RPL patients (p < 0.0001), with a median fold change of 0.29 (IQR: 0.12–0.67). Moreover, no substantial differences were found in relative expression of miR-126 and VEGFA mRNA among categories of various variables in RPL group respectively. Correlation analysis revealed a negative association between miR-126 and VEGFA expression in RPL cases (r = -0.165). In healthy controls, the miR-126 expression was positively correlated with expression levels of VEGFA mRNA with correlation coefficient (r) = 0.925; p < 0.01. However, the correlation between miR-126 and VEGFA mRNA was not statistically significant in the RPL group.

Conclusions

Our findings suggest that dysregulation of miR-126 and VEGFA is associated with RPL. These markers may serve as potential diagnostic and prognostic tools for idiopathic RPL. Furthermore, restoring the normal expression of these molecules could represent a novel therapeutic approach for this condition.